This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category 'Other. The cookies is used to store the user consent for the cookies in the category 'Necessary'. The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category 'Functional'. The cookie is used to store the user consent for the cookies in the category 'Analytics'. Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the 'Advertisement' category. Stripe sets this cookie cookie to process payments. These cookies ensure basic functionalities and security features of the website, anonymously. Necessary cookies are absolutely essential for the website to function properly. according to registry data, administration of the antidote PRAXBIND in patients with acute stroke followed by thrombolysis is effective, safe, and easy to perform.according to expert consensus, the combination of idarucizumab and IVT is suggested f or patients with acute ischemic stroke of administration of thrombolysis after prior neutralization of the effect of dabigatran with the antidote PRAXBIND is possible (indications for Praxbind include emergency procedures that may involve thrombolysis).IVT may be considered in patients with normal TT or TT 6h after the last dose of the drug indicates the absence of anticoagulant activity.

normal aPTT alone is not sufficient it does not completely rule out an elevated TT.intravenous thrombolysis (IVT) in patients with acute ischemic stroke is possible with dabigatran therapy if aPTT + TT, ECT, or HEMOCLOT values do not exceed the upper limits of the reference values (AHA/ASA 2013 III/C).

Idarucizumab mechanism of action